CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. - Wikidata - awgldk - TriplyDB

CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.

CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.

http://www.wikidata.org/entity/Q35600445

about

Oncogenes: The Passport for Viral Oncolysis Through PKR Inhibition Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade Viro-immune therapy: A new strategy for treatment of pancreatic cancer Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications Oncolytic virotherapy for human malignant mesothelioma: recent advances Measles to the Rescue: A Review of Oncolytic Measles Virus Trial Watch-Oncolytic viruses and cancer therapy Oncolytic viruses against cancer stem cells: A promising approach for gastrointestinal cancer Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors Polymeric Cups for Cavitation-mediated Delivery of Oncolytic Vaccinia Virus.Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.Gene and cell therapy for pancreatic cancer.Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling.Oncolysis by paramyxoviruses: preclinical and clinical studies.How to develop viruses into anticancer weapons.Association between CTLA-4 rs231775 polymorphism and hepatocellular carcinoma susceptibility.EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses Assessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly"?Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.Murine Tumor Models for Oncolytic Rhabdo-Virotherapy.Vaccinia virus, a promising new therapeutic agent for pancreatic cancer.Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers.Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition.Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity.Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy.Arming oncolytic viruses to leverage antitumor immunity.Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression.Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.Immunological landscape and immunotherapy of hepatocellular carcinoma.Fighting Cancer with Mathematics and Viruses.In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf.Targeting Melanoma with Cancer-Killing Viruses.A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.In situ vaccination for the treatment of cancer.State of play and clinical prospects of antibody gene transfer.

P2860

Q26739777-5F6236F9-C6ED-4D59-BD66-E6BE93AE74EC Q26769977-D2D7F86C-93E2-44E8-9A11-5A13E18DB929 Q26774641-B3E7FC5C-60F7-4B06-8131-CE8662D38E79 Q26775030-5E6E76AE-28D0-424D-AB12-EA1AA7CD4AAA Q26776553-BB8BD715-6B90-43FB-BBDE-5B5368F50D6A Q26826590-425C8DEC-4417-4055-94C0-D09A0BEE90D3 Q28072097-9EB1787F-82D0-4EBB-96BC-F3EA6AAA2748 Q28072347-D5EDFF80-2E07-4081-AC40-82E2F4A1B9BD Q28078939-216B7D6F-FE0D-471F-80EE-E9CA24DAC35A Q28086999-16DD1CB0-4ABC-4C82-94DF-0C49B820E6AC Q30369123-77F91BF5-B9B3-49F8-B2E3-2A36E1456828 Q33551626-25115913-11DB-4016-8126-EA0E2D342C9B Q33679505-C41E0523-7519-437C-9544-D8EED1273416 Q33725706-13F9C1C2-B069-465B-A505-427FE9123F02 Q35226511-9D9E9C92-9AD8-48DA-AD0C-65D6BEDD9396 Q35541787-11961666-4B50-490D-B960-ECEFCC06916B Q35789319-013143FB-81CD-4DD7-8C1C-5224AFDD87C8 Q35861933-81525749-9F36-47D5-BAD4-333060D3D589 Q36310887-7DE6CAD2-4E13-4D62-A934-9E8251EE4207 Q36464841-4B23F479-15E0-4865-98FD-9056D847FACE Q36549443-4C0661E8-96BE-4C2B-97C2-BA32E49104B4 Q36582819-DFE96C3F-2F4B-478D-815F-AE22F71DCF2D Q36664268-D8EE7E1B-2816-4D4E-8FFA-A12711470B9F Q36700481-66A4768B-7A27-42D2-934A-EC68AC6D4296 Q36751597-8EA82A46-80DD-4BB9-A257-7CE09465C2DE Q37158473-39D1CBA0-A3B9-4C4E-9876-34603787A575 Q37256174-1E36DAA5-1922-44CF-A07D-EF40C732F7E1 Q37380398-647998A2-8D8E-4F89-9221-6CDE40552E6A Q37651860-4506308F-918D-4CE7-850A-26C9456F4928 Q37736296-6DF6CDF0-5926-4794-98F7-272E02DA4E0E Q38470166-A6531218-5C09-4713-B543-04D267A4A0CB Q38525024-B9A83A08-5F5E-4E8A-9077-FA95B1E781B6 Q38534285-D8C463D6-7D2D-4B80-A0A1-7C154FEBDD97 Q38611895-A26DA3BD-FE98-4BB8-9E73-7DE5F891B88F Q38612646-D1E7789B-8B11-40DC-8C56-03B4CB87B5A4 Q38657642-353ACD3D-5DDE-4CFF-BF42-7EA749D2A1B0 Q38676416-4026A210-39E8-4071-A5C6-60B0B74953D8 Q38714321-18281885-6155-4D2D-A808-E2AC3C42246D Q38727470-A109741A-F714-4CD5-9F3B-EE4F20171AAE Q38737706-94D74C0B-8085-46A8-B224-694888DCBE3E

P2860

CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.

http://www.wikidata.org/entity/Q35600445

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.

@ast

CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.

@en

type

label

CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.

@ast

CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.

@en

prefLabel

CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.

@ast

CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.

@en

P1433

Q35600445-D1580144-3B1D-4450-B299-23E48821FF3D

P1476

Q35600445-43F70A93-C52C-46C4-9FC5-80CEAB3A7941

P2093

Q35600445-0BB0DC26-E111-43A7-9BFB-BB4DA7915BFB

Q35600445-1C1E1FC8-3D24-495D-80A4-4076D3063825

Q35600445-4D402609-BDE7-4275-8F7E-C23F014CCDED

Q35600445-92804768-9861-4269-B7D5-6668C33E3045

Q35600445-9932BE11-D000-4792-8836-651B13ADDEA5

Q35600445-C08CD181-98E4-449F-8E94-E7309F4D9A03

Q35600445-F44104F9-6102-4C7B-AF82-9E219C872111

Q35600445-F68E4CC5-DC2E-485F-8DE4-789F8D5C2130

P2860

Q35600445-1B6AEECD-7DD4-4AC8-8024-CDACBE7CFAC3

Q35600445-1DA2282C-EEE8-4619-B7D0-7D1B9E48EADB

Q35600445-23511DDD-6D0F-400C-AC79-1D32DC0DD6CA

Q35600445-29105DF0-BF0C-402B-AC5F-B21150D05F51

Q35600445-2A2F2EB6-1A71-44E3-9A60-D173BC4D5173

Q35600445-2C4BD1C2-DA2A-498D-9FB0-8AC85C800EDA

Q35600445-3E292E0A-9016-4E7D-921B-06EF48546764

Q35600445-4A2F432D-85D1-48A1-82F4-9EEE8358AA99

Q35600445-5311A19D-994C-4AC6-99A8-E8C84443437A

Q35600445-5658D2E2-F1E2-4772-A333-553DA8F63587

P304

Q35600445-BAE18D0E-12B0-4FA4-9246-D6DF65B93636

P31

Q35600445-3096BCBB-6CDC-4E7E-92BF-44222254A549

P356

Q35600445-FF67414C-F0DE-4B69-A1BB-B57DED1C352D

P433

Q35600445-DAD9B6E0-EB4A-4577-9656-EFB05BCAFF74

P478

Q35600445-A9277864-A7A3-47C9-BB62-96AC2C9B5470

P50

Q35600445-23D36452-A5E1-44B4-BDF6-FD0414408606

Q35600445-3B4FC045-2A38-49B5-A1EA-584E7971508F

Q35600445-57A2038B-0C16-4238-B7B4-7B037297E610

Q35600445-5E1055C6-7740-440E-A85C-528E42A20BAC

Q35600445-B7B3E103-372F-45CA-B675-5D71B1F9D85E

P577

Q35600445-BAB19FC3-0EE8-4892-872D-E1A3DCB988E5

P5875

Q35600445-106E8294-B504-46AF-9166-95B86B39AA08

P698

Q35600445-58EEC6E6-DE87-4C2B-906C-E29D3AD77EF9

P921

Q35600445-524BE791-5D21-4276-95A1-0F2048F0E2D0

Q35600445-6E1F144B-3868-4101-8D4B-357A98A750EB

P932

Q35600445-01126AEE-192A-4DE7-8F18-C4E0459829EE

P356

P1433

Molecular Therapy

P1476

CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.

@en

P2093

Christian Grossardt

http://www.w3.org/2001/XMLSchema#string

Diana Lutz

http://www.w3.org/2001/XMLSchema#string

Dirk Jäger

http://www.w3.org/2001/XMLSchema#string

Dirk M Nettelbeck

http://www.w3.org/2001/XMLSchema#string

Guy Ungerechts

http://www.w3.org/2001/XMLSchema#string

Johanna K Kaufmann

http://www.w3.org/2001/XMLSchema#string

Sascha Bossow

http://www.w3.org/2001/XMLSchema#string

Viktor Umansky

http://www.w3.org/2001/XMLSchema#string

P2860

New viruses for cancer therapy: meeting clinical needs

Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?

Thunder and lightning: immunotherapy and oncolytic viruses collide

Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

The blockade of immune checkpoints in cancer immunotherapy

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

CD28 and CTLA-4 coreceptor expression and signal transduction

P304

1949-1959

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2014.160

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Christof von Kalle

Christine E Engeland

Ivan Shevchenko

P577

2014-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265055918

http://www.w3.org/2001/XMLSchema#string

P698

25156126

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

4429737

http://www.w3.org/2001/XMLSchema#string